Clinical trials: Sudden Death
Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
Heart Rate Response to Regadenoson and Sudden Cardiac Death
The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.
- Trial name
- NCT01842035
- Testing
- regadenoson
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Alabama at Birmingham
Heart Arrest, Cardiac Arrest
Pre-arrival Instructions Effect on Bystander Cardiopulmonary Resuscitation (CPR).
The investigators hypothesized that pre-arrival instructions would increase the likelihood of bystanders performing Cardiopulmonary Resuscitation (CPR).
- Conditions
- Heart Arrest, Cardiac Arrest, Cardiopulmonary Arrest, Out of Hospital Cardiac Arrest
- Trial name
- NCT02007499
- Testing
- Pre-Arrival Instructions
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Medical College of Wisconsin
Death, Sudden, Cardiac
ASSURE WCD Clinical Evaluation - Conversion Efficacy Study
A multicenter single arm open label evaluation of the ASSURE Wearable Cardioverter Defibrillator (WCD) defibrillation waveform in adult cardiac patients
- Trial name
- ACE-CONVERT (NCT04132466)
- Testing
- Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Kestra Medical Technologies, Inc.
Death, Sudden, Cardiac, Ventricular Fibrillation
Automatic External Defibrillation Monitoring in Cardiac Arrest
We propose to randomize automatic external cardioverter/defibrillators (AECD) in patients who are at high risk for life-threatening abnormal heart rhythms (arrhythmias) and are admitted to the telemetry ward, all other treatments…
- Conditions
- Death, Sudden, Cardiac, Ventricular Fibrillation, Tachycardia, Ventricular
- Trial name
- NCT00382928
- Testing
- Defibrillation of pulseless VT/VF by AECD
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Foundation for Atlanta Veterans Education and Research, Inc.
Lupus Erythematosus, Systemic, Atrioventricular Block
Systemic Lupus Erythematous and Heart Conduction Disorders
Connective tissue diseases have been related to heart conduction disorders. The anti-Ro/SSA antibodies are thought to have a pathogenic role, and they most prevalent in systemic lupus erythematous (SLE).
- Conditions
- Lupus Erythematosus, Systemic, Atrioventricular Block, Sudden Death
- Trial name
- NCT02162992
- Testing
- No intervention
- Where
- Spain
- Volunteers
- 151 people
- Sponsor
- Germans Trias i Pujol Hospital
Primary Prevention of Sudden Cardiac Arrest, Secondary Prevention of Sudden Cardiac Arrest
S-ICD® System Post Approval Study
The purpose of the S-ICD Post Approval Study is to document long term safety and effectiveness outcomes associated with the implantation of the SQ-RX pulse generator and Q-TRAK electrode in a commercial clinical setting.
- Trial name
- NCT01736618
- Testing
- S-ICD System
- Where
- 87 sites in United States
- Volunteers
- 1,766 people
- Sponsor
- Boston Scientific Corporation
Cardiac Arrest, Sudden Death
A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest (APACAR2)
Cardiac arrest (CA) affects approximately 40,000 people in France. It is still a major cause of death in a young population. Management of CA is defined by international recommendations, detailed by learned societies in each…
- Trial name
- APACAR2 (NCT02527031)
- Testing
- ECMO Insertion on pre hospital setting, In Hospital ECMO
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Long QT Syndrome Type 3
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3.
- Trial name
- NCT02300558
- Testing
- Eleclazine
- Where
- 12 sites in United States, Canada and 6 more
- Volunteers
- 41 people
- Sponsor
- Gilead Sciences
Sudden Cardiac Arrest, Ventricular Arrythmia
Improve Sudden Cardiac Arrest Study
The purpose of this study is to demonstrate that primary prevention patients with one or more additional risk factors (1.5 prevention criteria: syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent…
- Trial name
- NCT02099721
- Testing
- ICD or CRT-D Device
- Where
- 93 sites in Argentina, Belarus and 14 more
- Volunteers
- 4,222 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypertrophic Cardiomyopathy, Sudden Cardiac Death
PRecIsion Medicine in CardiomyopathY
This is a retrospective cohort study of pediatric hypertrophic cardiomyopathy (HCM) patients using chart and registry review methodology.
- Trial name
- PRIMaCY (NCT04036799)
- Volunteers
- 572 people
- Sponsor
- The Hospital for Sick Children
Hunter Syndrome
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
This extension study of HGT-HIT-045 is designed to collect long-term safety data in pediatric participants with Hunter syndrome and cognitive impairment who are receiving intrathecal (IT) idursulfase-IT and intravenous (IV)…
- Trial name
- NCT01506141
- Testing
- Idursulfase-IT, Elaprase
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 15 people
- Sponsor
- Takeda
Syncope
Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study
The purpose of this study is to conduct an observational investigation of a novel care path used to manage emergency department (ED) presenting syncope patients on an outpatient basis.
- Trial name
- ASAP (NCT02188147)
- Testing
- Short Term Wearable Defibrillator
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- Zoll Medical Corporation
Sudden Cardiac Death
'Effect of CRT on Defibrillation Threshold Estimates' Study
The purpose of this prospective study is to evaluate the effect of cardiac resynchronization therapy (CRT) on the defibrillation threshold (DFT) estimates in cardiac resynchronization therapy defibrillators (CRT-D) patients.
- Trial name
- NCT00626093
- Testing
- Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Abbott Medical Devices
Sudden Cardiac Death, Heart Failure
Educational Videos to Address Racial Disparities in Implantable Cardioverter Defibrillator Therapy
VIVID is a prospective, multicenter, randomized clinical trial in African American patients that will to evaluate: (1) the effect of an educational video on knowledge of sudden cardiac death (SCD) and implantable cardioverter…
- Trial name
- VIVID (NCT02819973)
- Testing
- Educational Video1, Educational Video 2, Usual Care 3
- Where
- 14 sites in United States
- Volunteers
- 343 people
- Sponsor
- Duke University
Cardiac Arrest, Sudden
ASSURE WCD Clinical Evaluation - Detection and Safety Study
A prospective multicenter single arm open label study to evaluate ambulatory detection performance, arrhythmia detection and safety of the ASSURE™ Wearable Cardioverter Defibrillator (WCD).
- Trial name
- ACE-DETECT (NCT03887052)
- Testing
- ASSURE™ Wearable Cardioverter Defibrillator (WCD)
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- Kestra Medical Technologies, Inc.
Hunter Syndrome, Mucopolysaccharidosis II (MPS II)
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
Study TKT024EXT was a long-term, single-arm, open-label extension of Study TKT024, a one year Phase 2/Phase 3 registration study.
- Trial name
- NCT00630747
- Testing
- Idursulfase
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 94 people
- Sponsor
- Shire
Sudden Cardiac Death
POWER (Pulse Width Optimized Waveform Evaluation Trial)
The objective of this study is to compare the ULV (Upper Limit of Vulnerability)/DFT (Defibrillation Threshold) efficacy between the 2.5, 3.5 and 4.5 ms membrane time constant based biphasic defibrillation waveforms.
- Trial name
- NCT00311181
- Testing
- Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)
- Where
- 2 sites in United States
- Volunteers
- 217 people
- Sponsor
- Abbott Medical Devices
Mucopolysaccharidosis I, Mucopolysaccharidosis II
Clinical Trial of Growth Hormone in MPS I, II, and VI
The purpose of this study is to determine whether growth hormone is a safe and effective treatment for short stature in children with Mucopolysaccharidosis type I, II, and VI.
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
- Trial name
- NCT00748969
- Testing
- Somatropin (DNA origin)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Sudden Cardiac Death, Bradycardia
REASSURE AV Registry
Long term follow-up to monitor safety for patients implanted with a B301 ASSURE device.
- Trial name
- REASSURE (NCT01074034)
- Testing
- AV Therapy Assessment-B301 investigational device
- Where
- 36 sites in United States
- Volunteers
- 211 people
- Sponsor
- Boston Scientific Corporation
Sudden Cardiac Arrest
The Intrepid Clinical Engineering Study
The purpose of this research study is to collect clinical data to validate a software update for 12-lead electrocardiogram monitoring.
- Trial name
- NCT05636332
- Testing
- 12 lead Electrocardiogram
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Heartstream US LLC